Skip to content

Inspection Record

Valisure, LLC — FDA 483 Findings

US FDAInspected 2022-07-06Published 2023-01-06 4 findingsOther quality systemDeviation, CAPA, and investigationValidation and qualification

Inspectors Jonah S. Ufferfilge · Robert J. MartinThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

There are no systems in place to enable compliance with the requirements of the Food Drug and Cosmetic Act Section S82(c)(A) & (B) and (d)(A) & (B).

2Deviation, CAPA, and investigation

The firm's laboratory investigations are inadequate.

3Validation and qualification

The firm failed to adequately validate and/or verify analytical methods used in the evaluation of pharmaceutical products in that the firm failed to document the validation/verification process acceptance criteria, and an evaluation of the validity of the method outlining its intended use.

4Other quality system

Trading partners must have systems in place to make a notification of illegitimate product to FDA and immediate trading partners within 24 hours after making such a determination.

A record as of the US FDA document published on 2023-01-06. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Valisure, LLC company profile — full historyAll US FDA findings US FDA documents, 2023 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.